Helex

About Helex

Helex is an early‑stage biotechnology company operating in the United States and India that develops genomic medicines for high‑burden kidney diseases. Leveraging proprietary lipid‑nanoparticle delivery and its Epic‑Cure™ platform, Helex creates non‑viral, gene‑editing‑based therapeutics—such as CRISPR‑based treatments for autosomal dominant polycystic kidney disease—to address the large unmet need of chronic kidney disease patients.